ReviewInternational journal of molecular sciences2021
The Role of Endothelium in COVID-19.
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Noninsulin-based antihyperglycemic medications in patients with diabetes and COVID-19: A systematic review and meta-analysis.Journal of diabetes · 2023 · on this mapPooled it
- Microcirculatory impairment and increased arterial stiffness in pediatric Long COVID patients.European journal of pediatrics · 2026Article
- Monitoring Systemic Inflammatory Indices and Retinal Changes Over Time Following Initial Diagnosis of Diabetic Retinopathy.Journal of ophthalmology · 2026Article
- Article
- Molecular cross-talk between long COVID-19 and Alzheimer's disease.GeroScience · 2024Review
- Predictive Factors for Difficult Laparoscopic Cholecystectomies in Acute Cholecystitis.Diagnostics (Basel, Switzerland) · 2024Article
- The Review of Ophthalmic Symptoms in COVID-19.Clinical ophthalmology (Auckland, N.Z.) · 2024Review
- Substance P - a regulatory peptide with defense and repair functions. Results and perspectives for the fight against COVID-19.Frontiers in neurology · 2024Article
- Why have SGLT2 Inhibitors Failed to Achieve the Desired Success in COVID-19?Current pharmaceutical design · 2024Review
- Article
- Neurological Consequences, Mental Health, Physical Care, and Appropriate Nutrition in Long-COVID-19.Cellular and molecular neurobiology · 2023Review
- Implantation of engineered human microvasculature to study human infectious diseases in mouse models.iScience · 2023Article
- A potential host and virus targeting tool against COVID-19: Chemical characterization, antiviral, cytoprotective, antioxidant, respiratory smooth muscle relaxant effects of Paulownia tomentosa Steud.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2023Article
- COVID-19 Causes Ferroptosis and Oxidative Stress in Human Endothelial Cells.Antioxidants (Basel, Switzerland) · 2023Article
- Role of endothelial cells and angiotensin converting enzyme-II in COVID-19 and brain damages post-infection.Frontiers in neurology · 2023Article
- Molecular and pro-inflammatory aspects of COVID-19: The impact on cardiometabolic health.Biochimica et biophysica acta. Molecular basis of disease · 2022Review
- Review
- Calcium dobesilate reduces SARS-CoV-2 entry into endothelial cells by inhibiting virus binding to heparan sulfate.Scientific reports · 2022Article
- The Dual Pandemics of COVID-19 and Obesity: Bidirectional Impact.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2022Review
- Circulating Endothelial Cells: A New Possible Marker of Endothelial Damage in Kawasaki Disease, Multisystem Inflammatory Syndrome in Children and Acute SARS-CoV-2 Infection.International journal of molecular sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The 2019 novel coronavirus, known as severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) or coronavirus disease 2019 (COVID-19), is causing a global pandemic. The virus primarily affects the upper and lower respiratory tracts and raises the risk of a variety of non-pulmonary consequences, the most severe and possibly fatal of which are cardiovascular problems. Data show that almost one-third of the patients with a moderate or severe form of COVID-19 had preexisting cardiovascular comorbidities such as diabetes mellitus, obesity, hypertension, heart failure, or coronary artery disease. SARS-CoV2 causes hyper inflammation, hypoxia, apoptosis, and a renin-angiotensin system imbalance in a variety of cell types, primarily endothelial cells. Profound endothelial dysfunction associated with COVID-19 can be the cause of impaired organ perfusion that may generate acute myocardial injury, renal failure, and a procoagulant state resulting in thromboembolic events. We discuss the most recent results on the involvement of endothelial dysfunction in the pathogenesis of COVID-19 in patients with cardiometabolic diseases in this review. We also provide insights on treatments that may reduce the severity of this viral infection.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.